Evicenter
P&T meetings

Bezuclastinib

Nonadvanced systemic mastocytosis

Manufacturer
Cogent Biosciences
Regulatory submission
NDA submitted December 2025
62 sources

Section 6 of 6

References

62 sources

  1. AAAAI (2025) (opens in a new tab)
  2. AAAAI (2026) (opens in a new tab)
  3. Akin (2023) (opens in a new tab)
  4. Akin et al. (2026a) (opens in a new tab)
  5. Akin et al. (2026b) (opens in a new tab)
  6. ASH (2022) (opens in a new tab)
  7. AYVAKIT prescribing information (2023) (opens in a new tab)
  8. Blood (2023) (opens in a new tab)
  9. Boggs et al. (2026) (opens in a new tab)
  10. Bose et al. (2026) (opens in a new tab)
  11. Bulai Livideanu et al. (2025) (opens in a new tab)
  12. Canada’s Drug Agency (2026) (opens in a new tab)
  13. Canada’s Drug Agency (2026) (opens in a new tab)
  14. Chifotides and Bose (2025) (opens in a new tab)
  15. ClinicalTrials.gov NCT05186753 (opens in a new tab)
  16. Cogent Biosciences (opens in a new tab)
  17. Cogent Biosciences (2025) (opens in a new tab)
  18. Cogent Biosciences (2025) (opens in a new tab)
  19. Cogent Biosciences (2025) (opens in a new tab)
  20. Cogent Biosciences (2025) (opens in a new tab)
  21. Cogent Biosciences (2026) (opens in a new tab)
  22. Cogent Biosciences (2026) (opens in a new tab)
  23. Cogent Biosciences (2026) (opens in a new tab)
  24. Cogent Biosciences (2026) (opens in a new tab)
  25. Cogent Biosciences (2026) (opens in a new tab)
  26. Cogent Biosciences first quarter 2026 financial results (2026) (opens in a new tab)
  27. Cogent Biosciences investor overview (opens in a new tab)
  28. Cogent Biosciences presentation (2024) (opens in a new tab)
  29. Cogent Biosciences presentation (2025) (opens in a new tab)
  30. Costa et al. (2023) (opens in a new tab)
  31. Costanzo et al. (2025) (opens in a new tab)
  32. Dana-Farber Cancer Institute (opens in a new tab)
  33. Fahrenholz et al. (2026) (opens in a new tab)
  34. Farmer and Radia (2024) (opens in a new tab)
  35. FDA Orphan Drug Designations and Approvals (2023) (opens in a new tab)
  36. FDA Orphan Drug Designations and Approvals (2023) (opens in a new tab)
  37. George et al. (2025) (opens in a new tab)
  38. George et al. (2026) (opens in a new tab)
  39. Gotlib et al. (2023) (opens in a new tab)
  40. Guarnieri et al. (2021) (opens in a new tab)
  41. IQWiG (opens in a new tab)
  42. Jørgensen et al. (2025) (opens in a new tab)
  43. Marcus et al. (2026) (opens in a new tab)
  44. McMurray et al. (2024) (opens in a new tab)
  45. MD Anderson Cancer Center (opens in a new tab)
  46. Mesa et al. (2022a) (opens in a new tab)
  47. Mesa et al. (2022b) (opens in a new tab)
  48. NCCN (2024) (opens in a new tab)
  49. Norregaard et al. (2021) (opens in a new tab)
  50. Patent WO2024138005A1 (2024) (opens in a new tab)
  51. Pongdee et al. (2025) (opens in a new tab)
  52. Pongdee et al. (2026) (opens in a new tab)
  53. Rein et al. (2024) (opens in a new tab)
  54. Rein et al. (2025) (opens in a new tab)
  55. Rein et al. (2026a) (opens in a new tab)
  56. Rein et al. (2026b) (opens in a new tab)
  57. Siebenhaar et al. (2025a) (opens in a new tab)
  58. Siebenhaar et al. (2025b) (opens in a new tab)
  59. Syal et al. (2025) (opens in a new tab)
  60. Tse et al. (2024) (opens in a new tab)
  61. Valent et al. (2021) (opens in a new tab)
  62. Zeiger et al. (2025) (opens in a new tab)